Exceeding the limits of liver histology markers

Journal of Hepatology

Volumn 50, Issue 1, 2009, Pages 36-41

  Mehta, Shruti H ^a   Lau, Bryan ^a,b   Afdhal, Nezam H ^c   Thomas, David L ^a,b  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Biopsy; Hepatitis C virus; Liver disease; Surrogate markers; Validity

Indexed keywords

ARTICLE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DISEASE MARKER; GOLD STANDARD; HEPATITIS C VIRUS; HUMAN; LIVER BIOPSY; LIVER DISEASE; PREVALENCE; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY;

BIOLOGICAL MARKERS; BIOPSY; DIAGNOSTIC TESTS, ROUTINE; HEPATITIS C; HUMANS; LIVER; ROC CURVE; SENSITIVITY AND SPECIFICITY;

EID: 56949103477     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2008.07.039     Document Type: Article

References (38)

1. Strader D.B., Wright T., Thomas D.L., and Seeff L.B. Diagnosis, management, and treatment of hepatitis C. Hepatology 39 (2004) 1147-1171
2. Lok A.S., and McMahon B.J. Chronic hepatitis B: update of recommendations. Hepatology 39 (2004) 857-861
3. Proceedings of the European Association for the Study of the Liver (EASL) International Consensus Conference on Hepatitis B. September 14-16, 2002, Geneva, Switzerland. J Hepatol 2003;39:S1-S235.
4. Poynard T., Ratziu V., and Bedossa P. Appropriateness of liver biopsy. Can J Gastroenterol 14 (2000) 543-548
5. Bravo A.A., Sheth S.G., and Chopra S. Liver biopsy. N Engl J Med 344 (2001) 495-500
6. Imbert-Bismut F., Ratziu V., Pieroni L., Charlotte F., Benhamou Y., and Poynard T. Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study. Lancet 357 (2001) 1069-1075
7. Patel K., Gordon S.C., Jacobson I., Hezode C., Oh E., Smith K.M., et al. Evaluation of a panel of non-invasive serum markers to differentiate mild from moderate-to-advanced liver fibrosis in chronic hepatitis C patients. J Hepatol 41 (2004) 935-942
8. Sud A., Hui J.M., Farrell G.C., Bandara P., Kench J.G., Fung C., et al. Improved prediction of fibrosis in chronic hepatitis C using measures of insulin resistance in a probability index. Hepatology 39 (2004) 1239-1247
9. Forns X., Ampurdanes S., Llovet J.M., Aponte J., Quinto L., Martinez-Bauer E., et al. Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model. Hepatology 36 (2002) 986-992
10. Wai C.T., Greenson J.K., Fontana R.J., Kalbfleisch J.D., Marrero J.A., Conjeevaram H.S., et al. A simple non-invasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 38 (2003) 518-526
11. Kelleher T.B., Mehta S.H., Bhaskar R., Sulkowski M., Astemborski J., Thomas D.L., et al. Prediction of hepatic fibrosis in HIV/HCV co-infected patients using serum fibrosis markers: the SHASTA index. J Hepatol 43 (2005) 78-84
12. Leroy V., Monier F., Bottari S., Trocme C., Sturm N., Hilleret M.N., et al. Circulating matrix metalloproteinases 1, 2, 9 and their inhibitors TIMP-1 and TIMP-2 as serum markers of liver fibrosis in patients with chronic hepatitis C: comparison with PIIINP and hyaluronic acid. Am J Gastroenterol 99 (2004) 271-279
13. Foucher J., Chanteloup E., Vergniol J., Castera L., Le Bail B., Adhoute X., et al. Diagnosis of cirrhosis by transient elastography (FibroScan): a prospective study. Gut 55 (2006) 403-408
14. Saadeh S., Cammell G., Carey W.D., Younossi Z., Barnes D., and Easley K. The role of liver biopsy in chronic hepatitis C. Hepatology 33 (2001) 196-200
15. Shaheen A.A., Wan A.F., and Myers R.P. FibroTest and FibroScan for the prediction of hepatitis C-related fibrosis: a systematic review of diagnostic test accuracy. Am J Gastroenterol 102 (2007) 2589-2600
16. Bedossa P., Dargere D., and Paradis V. Sampling variability of liver fibrosis in chronic hepatitis C. Hepatology 38 (2003) 1449-1457
17. Colloredo G., Guido M., Sonzogni A., and Leandro G. Impact of liver biopsy size on histological evaluation of chronic viral hepatitis: the smaller the sample, the milder the disease. J Hepatol 39 (2003) 239-244
18. Poynard T., Halfon P., Castera L., Charlotte F., Le Bail B., Munteanu M., et al. Variability of the area under the receiver operating characteristic curves in the diagnostic evaluation of liver fibrosis markers: impact of biopsy length and fragmentation. Aliment Pharmacol Ther 25 (2007) 733-739
19. Poynard T., Munteanu M., Imbert-Bismut F., Charlotte F., Thabut D., Le Calvez S., et al. Prospective analysis of discordant results between biochemical markers and biopsy in patients with chronic hepatitis C. Clin Chem 50 (2004) 1344-1355
20. Dienstag J.L. The natural history of chronic hepatitis C and what we should do about it. Gastroenterology 112 (1997) 651-655
21. Afdhal N.H. Biopsy or biomarkers: is there a gold standard for diagnosis of liver fibrosis?. Clin Chem 50 (2004) 1299-1300
22. Zeremski M., and Talal A.H. Non-invasive markers of hepatic fibrosis: are they ready for prime time in the management of HIV/HCV co-infected patients?. J Hepatol 43 (2005) 2-5
23. Valenstein P.N. Evaluating diagnostic tests with imperfect standards. Am J Clin Pathol 93 (1990) 252-258
24. Phelps C.E., and Hutson A. Estimating diagnostic test accuracy using a "fuzzy gold standard. Med Decision Making 15 (1995) 44-57
25. Walter S.D., Irwig L., and Glasziou P.P. Meta-analysis of diagnostic tests with imperfect reference standards. J Clin Epidemiol 52 (1999) 943-951
26. NIH Consensus Statement on Management of Hepatitis C: 2002. NIH Consens State Sci Statements 2002;19:1-46.
27. Intraobserver and inter-observer variations in liver biopsy interpretation in patients with chronic hepatitis C. The French METAVIR Cooperative Study Group. Hepatology 1994;20:15-20.
28. Regev A., Berho M., Jeffers L.J., Milikowski C., Molina E.G., Pyrsopoulos N.T., et al. Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection. Am J Gastroenterol 97 (2002) 2614-2618
29. Bedossa P., and Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology 24 (1996) 289-293
30. Poynard T., Ratziu V., Benhamou Y., Thabut D., and Moussalli J. Biomarkers as a first-line estimate of injury in chronic liver diseases: time for a moratorium on liver biopsy?. Gastroenterology 128 (2005) 1146-1148
31. Castera L., Denis J., Babany G., and Roudot-Thoraval F. Evolving practices of non-invasive markers of liver fibrosis in patients with chronic hepatitis C in France: time for new guidelines?. J Hepatol 46 (2007) 528-529
32. La Haute Autorite de Sante (HAS). The HAS recommendations for the management of the chronic hepatitis C using non-invasive biomarkers, ; 2007 [accessed 17.05.08].
33. Castera L., Vergniol J., Foucher J., Le Bail B., Chanteloup E., Haaser M., et al. Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology 128 (2005) 343-350
34. Poynard T., Halfon P., Castera L., Munteanu M., Imbert-Bismut F., Ratziu V., et al. Standardization of ROC curve areas for diagnostic evaluation of liver fibrosis markers based on prevalences of fibrosis stages. Clin Chem 53 (2007) 1615-1622
35. Zhou X.H., Castelluccio P., and Zhou C. Nonparametric estimation of ROC curves in the absence of a gold standard. Biometrics 61 (2005) 600-609
36. Alonzo T.A., and Pepe M.S. Using a combination of reference tests to assess the accuracy of a new diagnostic test. Stat Med 18 (1999) 2987-3003
37. Walter S.D., and Irwig L.M. Estimation of test error rates, disease prevalence and relative risk from misclassified data: a review. J Clin Epidemiol 41 (1988) 923-937
38. Hall P., and Zhou X.H. Nonparametric estimation of component distributions in a multivariate mixture. Ann Statist 31 (2003) 201-224